The FDA has approved Jardiance® (empagliflozin) 10 mg to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, Boehringer Ingelheim and Eli Lilly report … more
Separately, the FDA granted Breakthrough Therapy Designation to Boehringer Ingelheim’s novel investigational therapy, BI 1015550 for the treatment of idiopathic pulmonary fibrosis. more